Appendix DQuality and Applicability of Included Studies

Publication Details

Table D-1. Quality and applicability for KQ 1 studies (MS Word, 104K)

Table D-2. Quality and applicability for KQ 2 studies (MS Word, 115K)

Table D-3. Quality and applicability for KQ 3 studies (MS Word, 102K)

References Cited in Appendix D

1.
Ajami GH, Cheriki S, Amoozgar H, et al. Accuracy of doppler-derived estimation of pulmonary vascular resistance in congenital heart disease: An index of operability. Pediatr Cardiol. 2011;32(8):1168–1174. [PubMed: 21779967]
2.
Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58(1):284–91. [PubMed: 18163505]
3.
Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735–40. [PubMed: 12480614]
4.
Bogdan M, Humbert M, Francoual J, et al. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax. 1998;53(12):1059–62. [PMC free article: PMC1745149] [PubMed: 10195079]
5.
Bonderman D, Wexberg P, Martischnig AM, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J. 2011;37(5):1096–103. [PubMed: 20693249]
6.
Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol. 2010;37(10):2064–70. [PubMed: 20634241]
7.
Cevik A, Kula S, Olgunturk R, et al. Quantitative Evaluation of Right Ventricle Function by Transthoracic Echocardiography in Childhood Congenital Heart Disease Patients with Pulmonary Hypertension. Echocardiography. 2012 [PubMed: 22494051]
8.
Ciurzynski M, Bienias P, Irzyk K, et al. Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis. Kardiol Pol. 2011;69(1):9–15. [PubMed: 21267956]
9.
Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37(2):401–9. [PubMed: 12540791]
10.
Condliffe R, Radon M, Hurdman J, et al. CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford) 2011;50(8):1480–6. [PubMed: 21447566]
11.
Dahiya A, Vollbon W, Jellis C, et al. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. Heart. 2010;96(24):2005–9. [PubMed: 21088122]
12.
Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997;36(2):239–43. [PubMed: 9133938]
13.
Farber HW, Foreman AJ, Miller DP, et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011;17(2):56–64. [PubMed: 21449993]
14.
Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–21. [PMC free article: PMC2720125] [PubMed: 19164700]
15.
Fitzgerald M, Fagan K, Herbert DE, et al. Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using doppler echocardiography. South Med J. 2012;105(6):300–305. [PubMed: 22665152]
16.
Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. Eur Respir J. 2011 [PubMed: 21778170]
17.
Frea S, Capriolo M, Marra WG, et al. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. Echocardiography. 2011;28(8):860–9. [PubMed: 21906161]
18.
Fukuda Y, Tanaka H, Sugiyama D, et al. Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension. J Am Soc Echocardiogr. 2011;24(10):1101–1108. [PubMed: 21775102]
19.
Ghio S, Matteo AD, Scelsi L, et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. Eur Heart J Suppl. 2004;6(6):F35–F39.
20.
Gialafos EJ, Moyssakis I, Psaltopoulou T, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. Mediators Inflamm. 2008;2008 [PMC free article: PMC2630404] [PubMed: 19190762]
21.
Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792–800. [PubMed: 16320330]
22.
Hammerstingl C, Schueler R, Bors L, et al. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. PLoS ONE. 2012;7(6) [PMC free article: PMC3369879] [PubMed: 22685577]
23.
Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol. 2008;35(3):458–65. [PubMed: 18203320]
24.
Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. Hepatobiliary Pancreat Dis Int. 2009;8(2):157–61. [PubMed: 19357029]
25.
Jansa P, Becvar R, Ambroz D, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clin Rheumatol. 2012;31(3):557–61. [PubMed: 22105781]
26.
Kovacs G, Maier R, Aberer E, et al. Assessment of pulmonary arterial pressure during exercise in collagen vascular disease: echocardiography vs right-sided heart catheterization. Chest. 2010;138(2):270–8. [PubMed: 20418368]
27.
Lindqvist P, Soderberg S, Gonzalez MC, et al. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. Eur J Echocardiogr. 2011;12(12):961–6. [PubMed: 22011836]
28.
Low AJ, Fowler D, Manghani MK, et al. Screening and Treating Pulmonary Arterial Hypertension in a Tertiary Hospital -based Multidisciplinary Clinic - The First 200 Patients. Intern Med J. 2011 [PubMed: 22032309]
29.
Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310–8. [PubMed: 16849664]
30.
McLean AS, Ting I, Huang SJ, et al. The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension. Eur J Echocardiogr. 2007;8(2):128–36. [PubMed: 16672193]
31.
Mourani PM, Sontag MK, Younoszai A, et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics. 2008;121(2):317–25. [PMC free article: PMC3121163] [PubMed: 18245423]
32.
Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004;43(4):461–6. [PubMed: 15024134]
33.
Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest. 1997;111(1):36–43. [PubMed: 8995990]
34.
Nakayama Y, Sugimachi M, Nakanishi N, et al. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. J Am Coll Cardiol. 1998;31(6):1367–71. [PubMed: 9581735]
35.
Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. J Magn Reson Imaging. 2009;30(5):973–80. [PubMed: 19856412]
36.
Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J. 2009;39(10):682–91. [PubMed: 19220532]
37.
Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl. 2000;6(1):85–91. [PubMed: 10648583]
38.
Rajagopalan N, Simon MA, Suffoletto MS, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. Echocardiography. 2009;26(5):489–94. [PubMed: 19054039]
39.
Rajagopalan N, Saxena N, Simon MA, et al. Correlation of tricuspid annular velocities with invasive hemodynamics in pulmonary hypertension. Congest Heart Fail. 2007;13(4):200–4. [PubMed: 17673871]
40.
Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. J Rheumatol. 2012;39(6):1265–1274. [PubMed: 22589263]
41.
Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2011;139(5):988–93. [PubMed: 20864617]
42.
Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. J Magn Reson Imaging. 2005;22(1):67–72. [PubMed: 15971176]
43.
Roule V, Labombarda F, Pellissier A, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. Cardiovasc Ultrasound. 2010;8:21. [PMC free article: PMC2898679] [PubMed: 20529278]
44.
Ruan Q, Nagueh SF. Clinical application of tissue Doppler imaging in patients with idiopathic pulmonary hypertension. Chest. 2007;131(2):395–401. [PubMed: 17296639]
45.
Ruiz-Irastorza G, Garmendia M, Villar I, et al. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmunity Reviews. 2012 [PubMed: 22841984]
46.
Sanli C, Oguz D, Olgunturk R, et al. Elevated Homocysteine and Asymmetric Dimethyl Arginine Levels in Pulmonary Hypertension Associated With Congenital Heart Disease. Pediatr Cardiol. 2012:1–9. [PubMed: 22526220]
47.
Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. AIDS. 2012 [PMC free article: PMC3897275] [PubMed: 22781217]
48.
Selimovic N, Rundqvist B, Bergh CH, et al. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2007;26(9):927–34. [PubMed: 17845932]
49.
Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int. 2008;28(7):657–60. [PubMed: 18092166]
50.
Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest. 2008;134(1):146–51. [PubMed: 18403670]
51.
Takatsuki S, Nakayama T, Jone PN, et al. Tissue Doppler Imaging Predicts Adverse Outcome in Children with Idiopathic Pulmonary Arterial Hypertension. J Pediatr. 2012 [PMC free article: PMC3508005] [PubMed: 22748515]
52.
Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr. 1996;9(6):838–47. [PubMed: 8943444]
53.
Tian Z, Liu YT, Fang Q, et al. Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. Chin Med J (Engl) 2011;124(12):1796–801. [PubMed: 21740835]
54.
Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study. Arthritis Research and Therapy. 2012;14(3) [PMC free article: PMC3446526] [PubMed: 22691291]
55.
Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation. 2001;71(4):572–4. [PubMed: 11258439]
56.
Toyono M, Harada K, Tamura M, et al. Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension. Pediatr Cardiol. 2008;29(1):65–9. [PubMed: 17786380]
57.
Tutar HE, Imamoglu A, Atalay S, et al. Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. Int J Cardiol. 1999;70(1):57–62. [PubMed: 10402046]
58.
Vlahos AP, Feinstein JA, Schiller NB, et al. Extension of Doppler-derived echocardiographic measures of pulmonary vascular resistance to patients with moderate or severe pulmonary vascular disease. J Am Soc Echocardiogr. 2008;21(6):711–4. [PubMed: 18187297]
59.
Vonk MC, Sander MH, van den Hoogen FH, et al. Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiogr. 2007;8(5):317–21. [PubMed: 16846757]
60.
Willens HJ, Chirinos JA, Gomez-Marin O, et al. Noninvasive differentiation of pulmonary arterial and venous hypertension using conventional and Doppler tissue imaging echocardiography. J Am Soc Echocardiogr. 2008;21(6):715–9. [PubMed: 18325734]
61.
Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27(12):1485–94. [PubMed: 16682379]
62.
Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006;98(4):525–9. [PubMed: 16893710]
63.
Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012;30(2):93–9. [PubMed: 21884013]
64.
Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. Cardiovasc Ther. 2011 [PubMed: 21884013]
65.
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med. 1996;334(5):296–302. [PubMed: 8532025]
66.
Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med. 2003;97(2):130–3. [PubMed: 12587962]
67.
Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation. 2010;122(2):164–72. [PubMed: 20585012]
68.
Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest. 2009;135(3):745–51. [PMC free article: PMC2715554] [PubMed: 18849405]
69.
Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart J. 2007;59(4):323–8. [PubMed: 19126937]
70.
Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. Am J Cardiol. 2006;98(4):530–4. [PubMed: 16893711]
71.
Brierre G, Blot-Souletie N, Degano B, et al. New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. Eur J Echocardiogr. 2010;11(6):516–22. [PubMed: 20185528]
72.
Bustamante-Labarta M, Perrone S, De La Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr. 2002;15(10 Pt 2):1160–4. [PubMed: 12411899]
73.
Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. Eur Heart J Suppl. 2004;6(6):F61–F67.
74.
Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol. 2009;36(4):760–7. [PubMed: 19208592]
75.
Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–23. [PubMed: 11597664]
76.
Badesch DB, Bodin F, Channick RN, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Ther Res Clin Exp. 2002;63(4):227–246.
77.
Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. Chest. 2007;132(3):786–92. [PubMed: 17646224]
78.
Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol. 2008;27(5):655–8. [PubMed: 18204995]
79.
D’Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2010 [PubMed: 21081251]
80.
Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. J Am Soc Echocardiogr. 2006;19(1):21–7. [PMC free article: PMC1934985] [PubMed: 16423665]
81.
Elstein D, Nir A, Klutstein M, et al. N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease. Pulm Pharmacol Ther. 2004;17(5):319–23. [PubMed: 15477128]
82.
Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. J Am Soc Echocardiogr. 2007;20(5):462–9. [PubMed: 17484984]
83.
Feliciano J, Cacela D, Agapito A, et al. Selective pulmonary vasodilators for severe pulmonary hypertension: comparison between endpoints. Rev Port Cardiol. 2005;24(3):399–404. [PubMed: 15929623]
84.
Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313–21. [PubMed: 16685024]
85.
Filusch A, Giannitsis E, Katus HA, et al. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. Clin Sci (Lond) 2010;119(5):207–13. [PubMed: 20412051]
86.
Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034–41. [PubMed: 16888289]
87.
Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. J Am Soc Echocardiogr. 2006;19(5):559–62. [PubMed: 16644441]
88.
Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9. [PubMed: 18506008]
89.
Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(21):1971–81. [PubMed: 19909879]
90.
Shapiro S, Pollock DM, Gillies H, et al. Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan. Am J Cardiol. 2012 [PMC free article: PMC4167616] [PubMed: 22858181]
91.
Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J. 2006;28(6):1190–4. [PubMed: 16971413]
92.
Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2010;140(3):272–8. [PubMed: 19070379]
93.
Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. Eur Respir J. 2002;19(4):664–71. [PubMed: 11998996]
94.
Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. Int Heart J. 2010;51(5):343–7. [PubMed: 20966607]
95.
Grapsa I, Pavlopoulos H, Dawson D, et al. Retrospective study of pulmonary hypertensive patients: is right ventricular myocardial performance index a vital prognostic factor? Hellenic J Cardiol. 2007;48(3):152–60. [PubMed: 17629178]
96.
Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. Isr Med Assoc J. 2008;10(2):117–20. [PubMed: 18432023]
97.
Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2009;22(5):523–9. [PubMed: 19307098]
98.
Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol. 2011;49(9):1258–62. [PubMed: 21887662]
99.
Hampole CV, Mehrotra AK, Thenappan T, et al. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol. 2009;104(6):868–72. [PubMed: 19733726]
100.
Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. Eur Respir J. 2012;39(4):939–44. [PubMed: 21885398]
101.
Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung. 2010;188(3):191–7. [PMC free article: PMC2886668] [PubMed: 20186422]
102.
Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group Circulation. 1997;95(6):1479–86. [PubMed: 9118516]
103.
Hiramoto Y, Shioyama W, Higuchi K, et al. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. J Cardiol. 2009;53(3):374–80. [PubMed: 19477379]
104.
Ho WJ, Hsu TS, Tsay PK, et al. Serial plasma brain natriuretic peptide testing in clinical management of pulmonary arterial hypertension. Acta Cardiol Sin. 2009;25(3):147–153.
105.
Homma A, Anzueto A, Peters JI, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant. 2001;20(8):833–9. [PubMed: 11502405]
106.
Jacobs W, Boonstra A, Marcus JT, et al. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. J Heart Lung Transplant. 2009;28(3):280–4. [PubMed: 19285621]
107.
Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with eisenmenger syndrome. J Card Fail. 2012;18(5):379–384. [PubMed: 22555267]
108.
Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J. 2011;41(3):235–44. [PubMed: 21118410]
109.
Knirsch W, Hausermann E, Fasnacht M, et al. Plasma B-type natriuretic peptide levels in children with heart disease. Acta Paediatr Int J Paediatr. 2011;100(9):1213–1216. [PubMed: 21388448]
110.
Kopec G, Tyrka A, Miszalski-Jamka T, et al. Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger’s Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist. Heart Lung and Circulation. 2012 [PubMed: 22819097]
111.
Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol. 2009;135(1):21–6. [PubMed: 18599134]
112.
Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 1999;99(25):3266–71. [PubMed: 10385501]
113.
Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest. 2005;128(4):2368–74. [PubMed: 16236896]
114.
Lorenzen JM, Nickel N, Kramer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest. 2011;139(5):1010–7. [PubMed: 20947652]
115.
Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radic Biol Med. 2004;37(7):1010–7. [PubMed: 15336317]
116.
Mahapatra S, Nishimura RA, Oh JK, et al. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2006;19(8):1045–50. [PubMed: 16880101]
117.
Mathai SC, Sibley CT, Forfia PR, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol. 2011;38(11):2410–8. [PubMed: 21965638]
118.
Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal ProB-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2011;108(11):1645–1650. [PubMed: 21890089]
119.
McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–22. [PubMed: 20430262]
120.
Frantz RP, McDevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. J Heart Lung Transplant. 2012;31(8):811–816. [PubMed: 22759797]
121.
Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105(20):2398–403. [PubMed: 12021227]
122.
Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol. 2009;147(5):737–43. [PMC free article: PMC3225273] [PubMed: 19775299]
123.
Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest. 2007;131(1):101–8. [PubMed: 17218562]
124.
Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. J Med Ultrason. 2009;36(4):201–206. [PubMed: 27277440]
125.
Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med. 2003;97(11):1230–6. [PubMed: 14635979]
126.
Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865–70. [PubMed: 10952954]
127.
Nakayama T, Shimada H, Takatsuki S, et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. Circ J. 2007;71(11):1785–90. [PubMed: 17965503]
128.
Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. Echocardiography. 2005;22(5):374–9. [PubMed: 15901287]
129.
Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589–96. [PubMed: 21885392]
130.
Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(5):534–41. [PubMed: 18565955]
131.
Njaman W, Iesaki T, Iwama Y, et al. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. Int Heart J. 2007;48(4):523–32. [PubMed: 17827824]
132.
Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circulation Journal. 2012;76(7):1729–1736. [PubMed: 22481098]
133.
Park MH, Scott RL, Uber PA, et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. Congest Heart Fail. 2004;10(5):221–5. [PubMed: 15470298]
134.
Pyxaras SA, Pinamonti B, Barbati G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. Eur J Echocardiogr. 2011;12(9):696–701. [PubMed: 21821609]
135.
Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214–9. [PubMed: 11923049]
136.
Rhodes CJ, Wharton J, Howard LS, et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart. 2011;97(13):1054–60. [PubMed: 21558476]
137.
Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant. 2012;31(7):735–743. [PubMed: 22480725]
138.
Schumann C, Lepper PM, Frank H, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers. 2010;15(6):523–32. [PubMed: 20528622]
139.
Sebbag I, Rudski LG, Therrien J, et al. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. Am J Cardiol. 2001;88(9):1060–3. [PubMed: 11704014]
140.
Shimony A, Fox BD, Langleben D, et al. Incidence and Significance of Pericardial Effusion in Patients With Pulmonary Arterial Hypertension. Can J Cardiol. 2012 [PubMed: 22717247]
141.
Soon E, Doughty NJ, Treacy CM, et al. Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. Pulm Circ. 2011;1(2):244–9. [PMC free article: PMC3198650] [PubMed: 22034610]
142.
Souza R, Jardim C, Julio Cesar, Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med. 2007;101(1):69–75. [PubMed: 16781131]
143.
Taguchi H, Kataoka M, Yanagisawa R, et al. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. Circulation Journal. 2012;76(6):1494–1500. [PubMed: 22447010]
144.
Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012;33(5):683–688. [PMC free article: PMC3366091] [PubMed: 22402804]
145.
Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol. 2012 [PMC free article: PMC3412194] [PubMed: 22511577]
146.
Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. Congenital Heart Disease. 2012;7(3):259–267. [PMC free article: PMC3355223] [PubMed: 22325151]
147.
Takeda Y, Tomimoto S, Tani T, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med. 2010;10:22. [PMC free article: PMC2873470] [PubMed: 20412580]
148.
Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003;108(7):844–8. [PubMed: 12900346]
149.
Utsunomiya H, Nakatani S, Okada T, et al. A simple method to predict impaired right ventricular performance and disease severity in chronic pulmonary hypertension using strain rate imaging. Int J Cardiol. 2011;147(1):88–94. [PubMed: 19747741]
150.
Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. J Am Soc Echocardiogr. 2009;22(12):1368–74. [PubMed: 19944957]
151.
Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res. 2008;63(3):321–7. [PubMed: 18287971]
152.
Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. Int J Cardiol. 2012 [PubMed: 22265324]
153.
Vizza CD, Letizia C, Petramala L, et al. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. Regul Pept. 2008;151(1–3):48–53. [PubMed: 18796317]
154.
Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. Chest. 2000;117(1):19–24. [PubMed: 10631193]
155.
Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171(11):1292–7. [PubMed: 15750042]
156.
Yamada Y, Okuda S, Kataoka M, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. Circulation Journal. 2012;76(7):1737–1743. [PubMed: 22498565]
157.
Yanagisawa R, Kataoka M, Taguchi H, et al. Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension. Circ J. 2012;76(5):1245–1252. [PubMed: 22333215]
158.
Yang SI, Chung WJ, Jung SH, et al. Effects of inhaled iloprost on congenital heart disease with eisenmenger syndrome. Pediatr Cardiol. 2012;33(5):744–748. [PubMed: 22349672]
159.
Yoshida S, Shirato K, Shimamura R, et al. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2012;28(6):1069–1076. [PubMed: 22506623]
160.
Zafrir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. Int J Cardiovasc Imaging. 2007;23(2):209–15. [PubMed: 16972146]
161.
Zeng WJ, Sun YJ, Xiong CM, et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in idiopathic pulmonary arterial hypertension. Chin Med J (Engl) 2011;124(11):1672–7. [PubMed: 21740775]
162.
Zhao QH, Peng FH, Wei H, et al. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol. 2012;110(3):433–439. [PubMed: 22560769]
163.
Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–34. [PubMed: 10733441]
164.
Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol. 2010;149(3):426–35. [PMC free article: PMC2914575] [PubMed: 20175775]
165.
Barst RJ, Ivy DD, Gaitan G, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children with Pulmonary Arterial Hypertension. Circulation. 2011 [PubMed: 22128226]
166.
Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl. 2007;13(6):875–85. [PubMed: 17539008]
167.
Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57. [PubMed: 16291984]
168.
Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417–22. [PubMed: 17985403]
169.
Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011;140(5):1274–83. [PubMed: 21546436]
170.
Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54. [PubMed: 16801459]
171.
Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093–100. [PubMed: 18572079]
172.
Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903. [PubMed: 19470885]
173.
Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30(6):632–43. [PubMed: 21256048]
174.
Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the Treatment of Pulmonary Arterial Hypertension. A Double-Blind 52-Week Uncontrolled Extension Study. J Am Coll Cardiol. 2012 [PubMed: 22818063]
175.
Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993;70(4):366–70. [PMC free article: PMC1025334] [PubMed: 8217447]
176.
Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2):137–49. [PubMed: 20022264]
177.
Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691–4. [PubMed: 17012628]
178.
Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30(6):1096–102. [PubMed: 17652314]
179.
Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–9. [PubMed: 15358690]
180.
Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183(12):1723–9. [PubMed: 21471085]
181.
Kemp K, Savale L, O’Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant. 2012;31(2):150–8. [PubMed: 22138355]
182.
McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41(2):293–9. [PubMed: 12548091]
183.
McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257–63. [PubMed: 16946127]
184.
Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome-A randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis. 2011;6(5):424–431. [PubMed: 21914136]
185.
Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–9. [PubMed: 12151469]
186.
Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104(5):731–40. [PubMed: 20153158]
187.
Reichenberger F, Mainwood A, Morrell NW, et al. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2011;24(1):169–73. [PubMed: 20601049]
188.
Rich JD, Glassner C, Wade M, et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest. 2012;141(1):36–42. [PubMed: 21659437]
189.
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903. [PubMed: 11907289]
190.
Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(8):1380–6. [PubMed: 12706935]
191.
Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65(10):1336–40. [PMC free article: PMC1798307] [PubMed: 16793845]
192.
Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112(7):485–91. [PubMed: 2107780]
193.
Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121(6):409–15. [PubMed: 8053614]
194.
Sastry BK, Raju BS, Narasimhan C, et al. Sildenafil improves survival in idiopathic pulmonary arterial hypertension. Indian Heart J. 2007;59(4):336–41. [PubMed: 19126939]
195.
Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–4. [PubMed: 11897647]
196.
Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–30. [PubMed: 18936500]
197.
Zeng WJ, Sun YJ, Gu Q, et al. Impact of Sildenafil on Survival of Patients With Idiopathic Pulmonary Arterial Hypertension. J Clin Pharmacol. 2011 [PubMed: 21956607]